Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in Florida

You’re a psychiatrist who’s noticed half your patients struggling with weight gain from antipsychotics or comorbid obesity fueling their depression. Or maybe you’re a PMHNP watching the GLP-1 boom and wondering if you can add weight management to your telehealth practice. The question isn’t ‘Should I?’ — it’s ‘Can I, legally?’

Here’s the reality: Yes, psychiatrists can prescribe weight-loss medications including GLP-1 agonists — you hold an unrestricted medical license. But the regulatory landscape is a minefield of DEA rules, state-specific telehealth laws, scope-of-practice limitations for NPs, and obesity treatment standards that vary wildly by state. Get it wrong and you’re looking at medical board complaints, DEA violations, or malpractice exposure.

This guide breaks down exactly what psychiatric providers need to know about prescribing weight-loss medications via telehealth in 2025–2026, with deep dives into the states where most of you practice: California, Texas, Florida, New York, Pennsylvania, and Illinois.

The Federal Baseline: DEA Rules for Telehealth Prescribing (Updated Through 2026)

Before we get into state rules, understand the federal layer: the Ryan Haight Online Pharmacy Act (2008) normally requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. Pre-COVID, that meant you couldn’t start a patient on phentermine (Schedule IV appetite suppressant) or ADHD stimulants without seeing them face-to-face first.

COVID changed everything. The DEA waived the in-person requirement during the Public Health Emergency. When that ended in 2023, providers panicked about a ‘telehealth cliff.’ But HHS and DEA have now extended telehealth flexibilities through December 31, 2026 — meaning you can still prescribe controlled substances via telemedicine to new patients without an initial in-person visit, at least federally.

What happens in 2027? The DEA is drafting permanent rules. Early proposals suggest they’ll create a ‘Special Telemedicine Registration’ pathway for Schedule III–V drugs and possibly allow limited Schedule II prescribing (like ADHD stimulants) for certain specialists. But expect restrictions — likely state-of-practice limits, caps on prescription volume, or mandatory 30-day supply limits initially. Watch for final rules in 2026.

Here’s what matters for weight-loss prescribing:

• GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Mounjaro) are NOT controlled substances. You can prescribe them via telehealth with zero DEA restrictions. Only standard prescribing rules apply.

• Phentermine (Adipex-P) IS a Schedule IV controlled substance. Under the current federal extension, you can prescribe it via telehealth to new patients through 2026. But you still need a DEA registration and must comply with state PDMP (Prescription Drug Monitoring Program) checks.

• Combination drugs (phentermine/topiramate) are also Schedule IV — same rules as phentermine alone.

Bottom line: The federal government currently allows telehealth prescribing of weight-loss controlled substances. But states can (and do) impose stricter rules. That’s where things get complicated.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The State Problem: Not All Telehealth Laws Are Created Equal

Federal law sets the floor — states can be more restrictive. And when it comes to weight-loss telehealth prescribing, state variation is massive. Some states like Florida have detailed obesity treatment regulations; others like Pennsylvania have virtually none. Some states like New York still require in-person exams for controlled substances; others like Texas don’t.

Let’s break down the priority states:

New York: The In-Person Requirement That Won’t Die

New York reinstated its pre-COVID stance in May 2025: you cannot prescribe controlled substances via telehealth without an in-person medical evaluation (10 NYCRR §80.63).

What this means practically:

• You can prescribe GLP-1s via telehealth (semaglutide, tirzepatide) with no in-person visit — they’re not controlled.

• You cannot start a new patient on phentermine via telehealth unless you’ve seen them in person first (or they’ve been examined by another NY provider in the past 12 months and you have records, or you’re covering for a colleague, or it’s a 5-day emergency supply for an existing patient).

• Established patients you’ve seen in person can continue controlled meds via telehealth follow-ups.

For PMHNPs: New York allows NP independent practice after 3,600 hours of supervised experience — but treating obesity as a psych NP is dicey. Your scope is mental health. If you’re prescribing weight-loss meds, you’re venturing into primary care/endocrinology territory. You’d be wise to either stick to GLP-1s for patients with binge-eating disorder (where there’s a psych indication) or collaborate informally with a primary care physician.

Compliance essentials for NY:

• Check the I-STOP PMP within 24 hours before prescribing any Schedule II–IV drug (every prescription, not just the first)
• Use e-prescribing for all prescriptions (mandatory in NY since 2016)
• Document telehealth consent (recommended, though not legally required for non-controlled meds)

Florida: Strict Standards, But Telehealth-Friendly

Florida is a paradox: very permissive on telehealth prescribing but very strict on how you treat obesity.

Telehealth prescribing rules (Fla. Stat. §456.47):

• Florida prohibits telehealth prescribing of Schedule II drugs (Adderall, oxycodone) except for psychiatric treatment, inpatient care, hospice, or nursing home patients.
• Schedule III–V drugs (phentermine) can be prescribed via telehealth with no restrictions.
• GLP-1s are wide open — not controlled.

But here’s the catch — Florida’s Board of Medicine has detailed obesity treatment standards (FAC 64B8-9.012):

• Patient must have BMI ≥30 (or ≥27 with comorbidities)
• You must conduct a full evaluation (can be via telehealth) including history, physical exam, and necessary tests
• Written informed consent required, outlining medication risks
• Re-evaluate at least every 3 months while patient is on weight-loss meds
• Provide the patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’

For PMHNPs: Florida psych NPs still require physician supervision (2024 legislation to grant autonomy failed). You’d need a supervising physician — ideally someone with obesity medicine credentials, not another psychiatrist — and explicit protocols covering weight-loss treatment.

Compliance essentials for FL:

• Check E-FORCSE PDMP before prescribing any controlled substance to patients ≥16 years
• Document quarterly follow-ups meticulously
• Avoid advertising ‘guaranteed weight loss’ — Florida Consumer Protection laws prohibit it
• If you’re not a physician, ensure your business structure complies with Florida’s prohibition on corporate practice of medicine

California: NP Independence Arriving, Medi-Cal Coverage Disappearing

California is telehealth-progressive but has quirks:

Telehealth prescribing: A telehealth exam meets the ‘appropriate prior examination’ requirement (Bus. & Prof. Code §2242) — no in-person visit needed if your video/phone evaluation meets the standard of care. California has no blanket ban on controlled substance telehealth prescribing.

NP scope: Major change coming. California’s AB 890 created a pathway for NP independent practice — as of January 2026, qualified NPs can practice without physician supervision. But here’s the rub: if you’re a PMHNP certified in psychiatric mental health, is obesity treatment within your scope? Arguably no — you’d be practicing outside your certification area. An FNP with independent practice authority? Much clearer.

The Medi-Cal bombshell: California’s Medicaid program will stop covering GLP-1 medications for weight loss effective January 2026. This shifts the market toward cash-pay telehealth models — potentially good for your practice economics, but it also means your patient pool skews to those who can afford $300–1,000/month out-of-pocket.

Compliance essentials for CA:

• Query CURES PDMP before first controlled substance prescription and at least every 4 months for ongoing therapy
• Document telehealth consent (Bus. & Prof. Code §2290.5)
• Use e-prescribing (mandatory)
• Respect Corporate Practice of Medicine — only physician-owned entities can provide medical services (this affects how you structure a telehealth business)

Texas: Delegation Required for NPs, PMP Checks Essential

Texas allows telehealth prescribing but has strict provider hierarchy rules.

Telehealth prescribing: Texas law allows valid patient relationships via synchronous audio-video. No in-person requirement for weight-loss meds (including phentermine). But you must provide follow-up care instructions and, with patient consent, send a report to their primary care provider within 72 hours.

NP/PA scope: Texas NPs and PAs must have Prescriptive Authority Agreements with supervising physicians. Want to prescribe phentermine? It must be explicitly listed in the PAA. PMHNPs can prescribe Schedule III–V under delegation — but again, treating obesity is outside typical psych scope, so you’d need a physician comfortable overseeing weight management (probably not a psychiatrist).

PDMP: Texas requires checking the Tx PMP before prescribing opioids, benzos, barbiturates, or carisoprodol. Phentermine isn’t on the mandatory list, but best practice (and most clinic policies) is to check for all controlled substances.

Compliance essentials for TX:

• Ensure your PAA covers weight-loss drugs if you’re an NP/PA
• Document PMP checks
• Use live video for initial evaluations (not just phone or questionnaire)
• Coordinate with patient’s primary care provider

Pennsylvania: Flexible, But No Specific Obesity Rules

Pennsylvania is refreshingly simple: no comprehensive telehealth statute, which means providers follow professional standards and federal law.

Telehealth prescribing: Pennsylvania allows it. The Medical Board expects you to conduct an appropriate evaluation (can be via video) and document it like an office visit. Under the DEA extension, you can prescribe controlled substances via telehealth through 2026.

PDMP: Check the PA PDMP before first prescription of opioids or benzos, and every time for ongoing therapy. For other controlled substances (stimulants, phentermine), check before the first prescription and as clinical judgment dictates.

NP scope: Pennsylvania CRNPs need Collaborative Agreements to prescribe. No independent practice yet (legislation pending but not passed as of 2025). A PMHNP treating obesity would need a collaborating physician who’s comfortable with weight management.

Compliance essentials for PA:

• Register with PA PDMP and query appropriately
• Use e-prescribing for controlled substances (required since 2023)
• Document thorough evaluations (PA doesn’t mandate specific obesity protocols, but standard of care applies)

Illinois: Full NP Independence, Audio-Only Telehealth Allowed

Illinois is NP-friendly and telehealth-permissive.

Telehealth prescribing: Illinois explicitly allows patient relationships via telehealth (no in-person requirement). Even audio-only telehealth is permitted in some cases, though video is recommended for initial weight-loss evaluations.

NP scope: Illinois has Full Practice Authority (FPA) for APRNs who complete 4,000 hours of clinical experience and additional training. With FPA, you can prescribe Schedule II–V controlled substances independently. A Psychiatric NP with FPA could theoretically run a weight-loss practice, but you’d be on shaky ground scope-wise unless you get additional obesity medicine training.

PDMP: Check the PMPnow database before prescribing Schedule II narcotics and every 90 days for ongoing opioid therapy. Not legally mandated for stimulants or phentermine, but most providers check anyway.

Compliance essentials for IL:

• If you have FPA, ensure your practice stays within your competency area
• Use e-prescribing (required for all controlled substances since 2023)
• Document telehealth encounters thoroughly

Psychiatrist vs. PMHNP: Who Can Do What?

Psychiatrists (MD/DO): You have unrestricted prescribing authority. Legally, you can prescribe weight-loss medications — you’re not limited to psych drugs. But you assume responsibility to practice competently. Consider:

• Getting additional training (American Board of Obesity Medicine certification, CME courses)
• Following obesity treatment guidelines (document BMI, comorbidities, lifestyle counseling)
• Coordinating with primary care (especially for metabolic monitoring — GLP-1s affect blood sugar, cardiovascular status)
• Being honest about your limitations (if you’re not comfortable managing severe obesity or complex metabolic issues, refer)

PMHNPs: Your scope is mental health. Prescribing weight-loss drugs solely for obesity is arguably outside that scope in most states. Options:

1. Work under physician supervision with a collaborating MD who has obesity medicine expertise
2. Focus on psychiatric indications — e.g., prescribing GLP-1s for patients with binge-eating disorder or using them to offset antipsychotic-induced weight gain (where there’s a mental health rationale)
3. Get additional certification — pursue obesity medicine training and ensure your state board recognizes expanded scope
4. Partner with primary care — co-manage patients with an FNP or internist who handles the metabolic side

Reality check: Many telehealth weight-loss companies hire PMHNPs and have them work under physician oversight. It’s legal if structured correctly, but the physician must be meaningfully involved — not just a name on paper.

The Economics: Is Telehealth Weight-Loss Worth It?

Let’s talk money, because that’s what you’re really wondering.

Traditional patient acquisition costs for psychiatric patients run $200–500+ when you factor in:

• SEO investment (6–12 months before meaningful traffic)
• Google Ads ($15–40/click for mental health keywords, most clicks don’t convert)
• Directory fees (Psychology Today, Zocdoc charge monthly subscriptions plus per-booking fees)
• Staff time to qualify leads
• No-show rates from cold leads
• Failed campaigns and testing

Telehealth platforms like Klarity Health use a different model: pay per appointment. You only pay when a qualified patient books with you — no upfront marketing spend, no monthly subscriptions, no gambling on ads. The per-appointment fee is typically similar to what you’d pay Zocdoc per booking, but you get:

• Pre-qualified patients matched to your specialty and availability
• Built-in telehealth infrastructure (no separate EMR/video platform costs)
• Insurance and cash-pay patient flow
• You control your schedule — only see patients when you want

For weight-loss services specifically, the cash-pay model is increasingly dominant (especially as insurers like Medi-Cal drop coverage). Patients pay $100–300+ per visit plus medication costs. If you’re using a platform that handles patient acquisition, you avoid the $3,000–5,000/month DIY marketing budget with uncertain ROI.

The trade-off: You pay per patient instead of owning the marketing channel. Long-term, some providers build their own SEO/referral network. Short-term (or if you’re scaling quickly), platforms remove the risk entirely.

Compliance Checklist: Don’t Get Burned

Whether you’re a psychiatrist or PMHNP, follow these rules to stay out of trouble:

Universal requirements:

• [ ] Licensed in the state where the patient is located (every visit)
• [ ] Verify patient location at each encounter
• [ ] Conduct appropriate evaluation (video preferred; document thoroughly)
• [ ] Check PDMP before prescribing controlled substances (required in most states)
• [ ] Use e-prescribing (mandatory in most states)
• [ ] Document informed consent for telehealth (required in CA, IL; recommended everywhere)
• [ ] Follow state-specific obesity treatment standards where applicable

For controlled substances (phentermine):

• [ ] Confirm state allows telehealth prescribing (NOT New York without in-person exam)
• [ ] Check PDMP every prescription in states that require it (PA for benzos/opioids, CA every 4 months, etc.)
• [ ] Maintain DEA registration
• [ ] Document medical necessity and safety assessment

For GLP-1s (not controlled):

• [ ] Document BMI and weight-loss indication
• [ ] Assess contraindications (thyroid cancer history, pancreatitis, etc.)
• [ ] Provide patient education on injection technique, side effects
• [ ] Schedule appropriate follow-ups (monthly early on, quarterly minimum in FL)
• [ ] Coordinate with primary care for metabolic monitoring

For PMHNPs:

• [ ] Ensure prescribing is within your scope or you have appropriate physician oversight
• [ ] Have written protocols/collaborative agreement covering weight-loss treatment
• [ ] Document additional training or certification if practicing outside traditional psych scope

When Telehealth Weight-Loss Makes Sense (And When It Doesn’t)

Good candidates for telehealth weight-loss prescribing:

• Psychiatrists treating patients with antipsychotic-induced weight gain
• Providers in states with clear telehealth rules (TX, FL, CA, IL)
• Practices comfortable with cash-pay models (insurance coverage is shrinking)
• Providers willing to coordinate with primary care for comprehensive management

Red flags — proceed with caution:

• PMHNPs in states requiring physician supervision without a qualified collaborating MD
• Practices in New York (unless you can arrange in-person exams for controlled substances)
• Pure online-only models with no patient relationship continuity (state boards are watching)
• Providers unwilling to follow quarterly follow-up requirements or metabolic monitoring

The Bottom Line

Can you prescribe weight-loss medications via telehealth as a psychiatric provider? Yes — with significant caveats based on your credential type, state, and medication choice.

GLP-1s are the low-hanging fruit: Not controlled, high demand, telehealth-friendly in all states. If you’re comfortable managing metabolic side effects and coordinating care, this is your lane.

Phentermine is trickier: Controlled substance rules vary wildly by state. Doable in most states through 2026 under federal extension, but watch for state-specific PDMP requirements and in-person mandates (New York).

Scope matters more than you think: Psychiatrists have broad authority but should practice within competence. PMHNPs need to be extra careful — either stay in your mental health lane or get proper oversight/training.

The regulatory landscape is shifting: DEA rules expire end of 2026. State telehealth laws are evolving (NP independence, insurance coverage changes). Stay current or risk compliance gaps.

Want to explore telehealth weight management without the marketing headaches? Platforms like Klarity Health handle patient acquisition, credentialing, and infrastructure — you just see patients and prescribe. No upfront spend, no SEO gamble, no failed ad campaigns. Just qualified patients matched to your availability.

Ready to expand your practice? Join Klarity’s provider network and start seeing weight-loss patients via telehealth — we handle compliance guidance, patient acquisition, and platform support so you can focus on what you do best: clinical care.

FAQ: Weight-Loss Telehealth Prescribing for Psychiatrists

Q: Can I prescribe Ozempic (semaglutide) via telehealth without seeing the patient in person?

A: Yes, in all 50 states. Semaglutide (Ozempic, Wegovy) is not a controlled substance, so the Ryan Haight Act doesn’t apply. You need to conduct an appropriate telehealth evaluation (usually video), document medical necessity (BMI criteria), and follow state-specific obesity treatment standards where they exist (like Florida’s quarterly follow-ups). Coordinate with the patient’s primary care provider for metabolic monitoring.

Q: What about phentermine — can I prescribe it via telehealth?

A: Depends on your state. Phentermine is Schedule IV controlled. Under the current federal DEA extension (through Dec 31, 2026), you can prescribe it via telehealth to new patients in most states. Exception: New York requires an in-person exam first for any controlled substance. Also check state PDMP requirements — California requires checking CURES every 4 months, Pennsylvania requires checking before each benzo/opioid prescription, etc.

Q: As a PMHNP, can I offer weight-loss treatment?

A: Legally complex. Your scope is psychiatric mental health — treating obesity as a primary condition is arguably outside that scope in most states. Options: (1) Work under physician supervision with a collaborating MD who has obesity medicine credentials; (2) Focus on psychiatric indications (e.g., GLP-1s for binge-eating disorder or to offset antipsychotic weight gain); (3) Get additional obesity medicine certification; (4) Partner with primary care providers. Independent practice laws (like California’s AB 890 or Illinois FPA) don’t automatically expand your scope beyond your certification area.

Q: Do I need special certification to prescribe weight-loss medications?

A: No special license required — any physician can prescribe obesity medications. However, consider: (1) Additional training (American Board of Obesity Medicine certification) bolsters your credibility and competence; (2) Some states have specific obesity treatment rules (Florida requires documented BMI, informed consent, quarterly follow-ups); (3) Malpractice insurers may scrutinize your qualifications if you’re practicing outside your usual specialty. For PMHNPs, see previous question.

Q: What are the biggest compliance risks in telehealth weight-loss prescribing?

A: (1) Prescribing controlled substances in states with in-person requirements (New York); (2) Failing to check PDMPs as required by state law; (3) Inadequate evaluation or follow-up — state medical boards expect comprehensive care, not ‘pill mill’ prescribing; (4) Practicing outside your scope as an NP without proper oversight; (5) Corporate practice of medicine violations in states like California if your business structure is wrong; (6) False advertising (guaranteeing results, using ‘FDA approved’ for off-label uses).

Q: How often do I need to see weight-loss patients?

A: Varies by state and standard of care. Florida explicitly requires re-evaluation every 3 months minimum. Most obesity medicine guidelines recommend monthly follow-ups early in treatment (first 3 months) for dose titration and side effect monitoring, then quarterly once stable. For GLP-1s, you’ll need to adjust doses every 4 weeks initially. For phentermine, most providers see patients monthly (it’s typically prescribed for short-term use, though some use it long-term off-label).

Q: Can I prescribe weight-loss meds to out-of-state patients?

A: Only if you’re licensed in the state where the patient is physically located. No federal telehealth license exists (except for VA/IHS). You need either: (1) Full license in each state; (2) Participation in Interstate Medical Licensure Compact (physicians) or Nurse Licensure Compact (NPs) where applicable; (3) Some states offer special telehealth registrations (Florida, for example) — but these often prohibit controlled substance prescribing.

Q: What happens when the DEA’s telehealth extension expires at the end of 2026?

A: The DEA is drafting permanent rules. Expect some version of telehealth prescribing to continue, but likely with new restrictions: special registrations, limits on Schedule II prescriptions, mandatory in-person visits after initial telehealth prescriptions, etc. Weight-loss meds (mostly Schedule IV or non-controlled) will probably remain accessible via telehealth, but watch for final rules in late 2025/early 2026. If you’re prescribing phentermine via telehealth, plan for potential requirement to see patients in person periodically starting 2027.

Q: Is it worth joining a telehealth platform vs. building my own practice?

A: Platform pros: Immediate patient flow, no marketing costs, built-in compliance/credentialing support, infrastructure included (EMR, video, billing). You pay per appointment but avoid the $3,000–5,000/month DIY marketing gamble. DIY pros: You own the patient relationships, keep 100% of revenue after your actual expenses, build long-term equity in your brand. Reality: Most successful providers do both — start with a platform for immediate income and patient volume, then build organic referral/SEO over 12–24 months. The platform removes risk while you scale.

Citations and References

1. U.S. Department of Health & Human Services – ‘HHS and DEA Announce Extension of Telemedicine Flexibilities for Prescribing Controlled Medications Through End of 2026’ (January 2, 2026) – Official federal policy statement on DEA telehealth extension. www.hhs.gov

2. Florida Statutes §456.47 – ‘Use of Telehealth to Provide Services’ (Florida Telehealth Act, effective 2019, accessed November 2025) – Official Florida law governing telehealth practice and prescribing restrictions. florida.public.law

3. Florida Administrative Code 64B8-9.012 – ‘Standards for the Prescription of Drugs to Treat Obesity’ (Florida Board of Medicine, effective August 8, 2022) – State regulation detailing obesity treatment requirements including BMI thresholds, informed consent, and quarterly follow-ups. regulations.justia.com

4. Goodwin Law – ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ Client Alert (March 30, 2024) – Legal analysis of state-specific weight-loss prescribing rules covering Florida, New Jersey, Virginia, and other jurisdictions. www.goodwinlaw.com

5. New York Codes, Rules & Regulations Title 10, §80.63 – ‘Use of Controlled Substances for Treatment’ (NY Department of Health, amended May 2025) – Official New York regulation establishing in-person exam requirements for controlled substance prescribing via telehealth. www.law.cornell.edu

6. California Medical Association – ‘GLP-1 medications for weight loss will no longer be covered by Medi-Cal’ (December 2, 2025) – Official announcement of California Medicaid coverage policy change effective January 2026. www.cmadocs.org

7. Medical Director Compliance Consulting – ‘California Weight Loss Clinic & Telehealth Compliance Guide (2025)’ – Comprehensive state-specific compliance guidance covering Corporate Practice of Medicine, NP scope, PDMP requirements, and telehealth standards. www.medicaldirectorco.com

8. Medical Director Compliance Consulting – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ – Texas-specific guidance on prescriptive authority agreements, delegation rules, and PDMP requirements. www.medicaldirectorco.com

9. Center for Connected Health Policy (CCHP) – ‘State Telehealth Policies: Online Prescribing’ (updated November 21, 2025) – Comprehensive database of state-by-state telehealth prescribing laws and requirements. www.cchpca.org

10. Fierce Healthcare – ‘Primary care doctors concerned about patient risks from telehealth prescribers of GLP-1s: survey’ by Heather Landi (February 13, 2025) – Industry report on physician concerns regarding telehealth weight-loss prescribing practices and patient safety. www.fiercehealthcare.com

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated